Currently Enrolling Trials

This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/impaired glucose tolerance and/or uncontrolled systolic hypertension (high blood pressure). To learn more, click here.

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD). To learn more, click here. 

The purpose of the CIN-102-121 study is to test how the study drug, CIN-102, may work in people with idiopathic or diabetic gastroparesis. Gastroparesis, also known as delayed gastric emptying, is a condition that affect the normal movement of the stomach muscles. Normaly, the stomach empties soon after eating a meal. With gastroparesis, it takes food much longer to empty from the stomach. Delayed emptying results in poor breakdown of food and uncomfortable symptoms.  To learn more, click here

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab (Repatha) on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event. To learn more, click here

This study is for women in menopause with hot flashes. Menopause, a normal part of aging, is the time of a woman’s last period. Hot flashes can interrupt a woman’s daily life. The purpose of this study is to find out how safe it is for these women to take fezolinetant long term (up to 52 weeks). To do that, the study will look at the number and severity of the “adverse events.” Those are the side effects that study participants have while they are in the study. To learn more about this study, click here.

Consider joining the TRAVERSE research study for men age 45-80 who have symptoms of low testosterone (hypogonadism) and have a history or risk of heart disease or stroke.

If you volunteer and qualify, your participation will last up to approximately 5 years. To learn more visit our contact us page or click here.

Randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor & licogliflozin combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. To learn more, click here

This is a multi-center, randomized, double-blind, parallel group, placebo controlled trial to evaluate the contribution of Triamcinolone Hexacetonide (TH) to pain relief, both in terms of magnitude and duration, when used within a single injection of Cingal® compared to a single injection of TH in subjects with OA of the knee.To learn more, click here.

The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time. To learn more about this study, click here. 

We need more treatment options for people with type 2 diabetes. Clinical research brings people together to gather information to advance science and medicine. It does not replace your regular medical care. This clinical research study is assessing different doses of a study drug.  The goal is to find out if any dose of the study drug is better for controlling blood sugar levels in type 2 diabetes than placebo. To learn more about this study, click here

Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice. To learn more, click here

Don't see a study that you qualify for?

Contact us to be added to interest list and you’ll be the first to know about our future studies! Send us a message by clicking the “contact us” button or call us at +1-843-851-7098.